Background: There are many theories to explain the origin and development of cancer, and it is a multistep process. It depends on many genes that control functions such as growth, proliferation, migration, invasion, metastasis, and angiogenesis. Ameloblastoma is a tumor of odontogenic epithelium, 80% of which occur in the jaw and often painlessly enlarge the jaw and cause facial deformity. Although ameloblastoma is a benign tumor, it is a locally invasive tumor and has a recurrence rate of up to 90% after surgery. It can also transform into cancer. According to the results of the researchers, ameloblastoma cells grow and infiltrate. The current standard treatment for ameloblastoma includes osteotomy, which is divided into marginal mandibular, segmental maxillary, partial maxillary, or total maxillary resection, depending on the location of the tumor. Although these surgical treatments are somewhat effective, the results often result in jaw deformity and facial deformity. Therefore, it is necessary to actively search for specific therapeutic strategies. Recent studies have begun to investigate the relationship between the activation of abnormal signaling pathways and ameloblastoma invasion. The complex interactions between signaling pathway elements, target genes, and molecular entities regulate tumor cell growth, apoptosis, and other key pathological phenomena in various signaling pathways. The results of other researchers have shown that the Notch signaling pathway is important in promoting ameloblastoma cell invasion. However, the role of the Notch signaling pathway and its related proteins in ameloblastoma cell invasion remains unclear. Our study investigated how inhibition of the Notch signaling pathway affects ameloblastoma cell invasion and investigated the relationship between them. We conducted a study to determine how this pathway affects ameloblastoma cell invasion by inhibiting the Notch signaling pathway in ameloblastoma cells. Aim: To investigate the effect of Notch signaling pathway inhibitors on ameloblastoma cell invasion. Materials and Methods: The study was conducted at the Experimental Research Base of Affiliated Hospital of Chifeng University, Inner Mongolia, China, using quantitative research methods and experimental research designs. The effect of FLI-06 on the infiltration of AB cells after inhibition of the Notch signaling pathway was studied by Transwell method. The ameloblastoma cell lines used in the study were obtained from the Experimental Research Base of Affiliated Hospital of Chifeng University. The Notch signaling pathway inhibitor FLI-06 was purchased from Absin Bioscience Inc. (Absin® CAS: 313967-18-9), Shanghai. Results: After staining the cells in the Transwell (Lower chamber) with Amethyst dye, the number of AB cells inhibited by FLI-06 was observed under a microscope. The cell permeability of the control group was estimated to be 100%, while the cell permeability of the experimental group was 25%. The infiltration activity of ameloblastoma cells was 1.37±0.06%, and the number of infiltrating cells was 137.20±25.55, while the infiltration activity of normal oral mucosa cells was 0.12±0.01%, and the number of infiltrating cells was 80.40±3.36. The number of AB cells after inhibition with FLI-06 was 34.60±6.95, and the number of cells in the control group using simple culture medium was 137.20±25.55. Conclusion Inhibition of the Notch signaling pathway with FLI-06 reduced ameloblastoma cell invasion

Background: Ameloblastoma (AB) is an odontogenic epithelial tumor. 80% of ameloblastomas occur in the jaw and often painlessly enlarge the jaw and cause facial deformity. Ameloblastoma is usually treated with a complete osteotomy, which is divided into three types: partial maxillary marginal resection, maxillary sinus resection, and total maxillary resection. These surgical procedures cause jaw deformity and facial trauma, so effective treatment methods with minimal trauma are still being sought in medicine. In order to develop new drugs for the treatment of ameloblastoma, it is necessary to study the molecular mechanisms that inhibit the proliferation of cancer cells. In recent years, it has been established that ameloblastoma is caused by abnormal activation of signaling pathways. Multiple signaling pathway regulators, target genes, and molecular interactions are involved in tumor cell proliferation and apoptosis. Previous studies have shown that blocking key signaling pathways is not only a therapeutic option in clinical practice, but also a useful tool in selecting tumor resection sites. Therefore, studying the molecular level of the Notch signaling pathway in the proliferation of ameloblastoma cells is of great importance for the treatment of the disease. Studies have shown that many factors of the Notch signaling pathway play important roles in promoting or inhibiting different tumors. The Notch signaling pathway promotes tumor cell proliferation by regulating CDK1, Cyclin D1, HES-1, and COX-2. Chinese researchers Li Wenchao and Baolidao’s research team have studied factors related to AB proliferation and invasion for the past decade, and have identified the roles of factors such as COX-2, Survivin, Akt, and PI3K in AB proliferation and invasion, and have successfully cultured primary ameloblastoma cells. However, the exact role of the Notch signaling pathway in AB cell proliferation has not been clearly studied. Aim: To study the effect of Notch signaling pathway inhibitors on ameloblastoma cell proliferation. Materials and Methods: The study was conducted at the Experimental Research Base of Affiliated Hospital of Chifeng University, Inner Mongolia, China, using quantitative research methods and experimental research designs. The expression of Notch1, Cyclin D1, and CDK1 genes in AB cells was detected using real-time polymerase chain reaction. The effect of FLI-06 on the proliferation of AB cells after inhibition was studied by counting (CCK8) method. The ameloblastoma cell lines used in the study were obtained from the Experimental Research Base of Affiliated Hospital of Chifeng University. The Notch signaling pathway inhibitor FLI-06 was purchased from Absin Bioscience Inc. (Absin® CAS: 313967-18-9), Shanghai. Results: In the study, real-time polymerase chain reaction analysis showed that the expression of Cyclin D1 in AB cells was 7.01 times higher than that in normal oral mucosa cells, the expression of CDK1 was 2.63 times higher, and the expression of Notch1 was 4.95 times higher. The cell proliferation of the control group was calculated as 100% by the AB cell proliferation inhibitor (CCK8) method, and compared with the experimental group, the cell proliferation of the group added with 5.0μM FLI-06 was 53.98%, 46.53% in the 10.0μM concentration group, and 22.33% in the 20.0μM concentration group. Conclusion Notch1, Cyclin D1, and CDK1 expression in ameloblastoma were significantly different from that in normal oral mucosa cells. Inhibition of the Notch signaling pathway with FLI-06 reduced ameloblastoma cell proliferation.

Background: Group B Streptococcus (GBS), also referred as Streptococcus agalactiae, is one of the leading causes of life-threatening invasive diseases such as bacteremia, meningitis, pneumonia and urinary tract infection in pregnant women and neonates. Rates of GBS colonization vary by regions, but large-sample studies on maternal GBS status are limited in southern China. As a result, the prevalence of GBS among pregnant women and its associated risk factors and the efficacy of intrapartum antibiotic prophylaxis (IAP) intervention in preventing adverse pregnancy and neonatal outcomes remain poorly understood in Inner Mongolia, China. Objective: This study was to investigate the colonization rate of Group B Streptococcus (GBS) during pregnancy, and to evaluate the influence of GBS colonization on pregnancy and birth outcomes in Inner Mongolian women, China Material and Method: A prospective case control study. Setting Data of 981 pregnant women from 2023 were collected from the Affiliated Hospital of Chifeng University, Inner Mongolia, China. Primary outcome measures: The incidence rates of GBS colonization and premature rupture of membranes, meconium-stained amniotic fluid, chorioamnionitis, postpartum hemorrhage and fetal distress. Results: Of the 981 pregnant women included in this study, 327 developed GBS colonization. The occurrence of GBS colonization not varied among different ethnic groups. Our data revealed that premature rupture of membranes (PROM) meconium-stained amniotic fluid, chorioamnionitis, postpartum hemorrhage and fetal distress were more common in pregnant women colonized with GBS than in pregnant women not colonized with GBS. The incidence for PROM, meconium stained amniotic fluid, chorioamnionitis, postpartum hemorrhage and fetal distress in infants of pregnant women colonized with GBS was 19.7% (OR=1.5; 95% CI, 0.981 to1.964), 8.3% (OR=2.2; 95% CI, 1.320 to 3.653), 11.3%, (OR= 1.6; 95% CI, 0.324 to 0.77), 8.2% (OR=1.0; 95% CI, 0.99-2.112), 4.1% (OR=6.54; 95% CI, 2.887 to14.805) respectively. Conclusion Maternal GBS colonization, longer duration of membrane rupture were all major risk factors associated with GBS colonization in Inner Mongolian Chinese women. Pregnant women colonized with GBS were more predisposed to PROM, meconium-stained amniotic fluid, chorioamnionitis and postpartum hemorrhage. Infant GBS colonization was associated with increased risk of fetal distress.

ObjectiveHenoch-Schönlein purpura（HSP） is one of the dominant diseases in Mongolian medicine. Qishun Baolier（QSBLE）， as the main prescription for the treatment of HSP， has significant clinical effect， but its mechanism is not yet clear. Baed on this， this study is intended to screen the differentially expressed proteins before and after treatment， and preliminarily explore the molecular mechanism of QSBLE in the treatment of HSP. MethodTaking oneself as the control， 30 HSP patients aged 6-45 years were collected， and QSBLE was taken orally at 12：00 and 24：00， respectively. The dose was adjusted according to age and the course of treatment was one week. The distribution of proteinuria， hematuria and skin purpura of all patients were determined before and after treatment. The serum samples of 10 patients with clinically significant remission after QSBLE treatment were randomly selected for proteomics. Isobaric tags for relative and absolute quantification（iTRAQ） combined with liquid chromatography tandem mass spectrometry（LC-MS/MS） was used to analyze the proteins in serum of HSP patients before and after treatment， and differential proteins were analyzed bioinformatically and the protein-protein interaction（PPI） networks were constructed. ResultA total of 378 proteins were identified from serum， including 18 differentially expressed proteins， of which 15 proteins were up-regulated and 3 proteins were down regulated. Bioinformatics showed that the differential proteins were mainly involved in biological processes such as immune response， immunoglobulin production， phagocytosis， adaptive immune response before and after treatment. Biological processes， pathways and proteins were used to construct the PPI network， the proteins represented by immunoglobulin heavy constant γ1（IGHG1）， immunoglobulin λ-chain 7-43（IGLV7-43）， gelsolin（GSN） and 60 kDa heat shock protein（HSPD1） were involved in biological processes and related pathways such as adaptive immune response， immunoglobulin production， leukocyte-mediated immunity， regulation of stress response， regulation of immune system processes， regulation of trauma response， and these proteins were at the center of the PPI network. ConclusionQSBLE may play a role in the treatment of HSP by regulating the expression of IGHG1， IGLV7-43， GSN， HSPD1 and other key proteins to affect immune-related biological processes.

Sugemule-10, one of the traditional Mongolian medicine (TMM) formulae, is derived from Four Medical Classics (Vol. 4) and composed of 10 Mongolian medicines. It is used to treat kidney cold, low back pain, urinary obstruction, kidney/bladder stones, and is the main prescription for kidney cold. The current research on Sugemule-10 is mostly focused on its clinical efficacy, and few papers are available upon its historical changes. Therefore, we systematically reviewed Sugemule-10 from the aspects of prescription source, prescription interpretation, efficacy evolution, and modern clinical applications.

OBJECTIVE：To establish a method for the content determination of apigenin and piperine in the water extract as well as eucalyptol and cumin aldehyde in the volatile oil of Mongolian medicine Sugmel- 3 decoction. METHODS ：HPLC method was adopted for the content determination of apigenin and piperine. GC method was used for the content determination of eucalyptol and cumin aldehyde. The determination of HPLC method was performed on Agilent Eclipse XDB-C 18 column with mobile phase consisted of methanol- 0.1％ phosphoric acid aqueous solution at flow rate of 1.0 mL/min；the detection wavelength was set at 225 nm（apigenin）and 342 nm（piperine）；the column temperature was set at 30 ℃ with sample size of 10 μL. The determination of GC method was performed on Dimensions SH-Rtx- 1 capillary column with high-purity hydrogen as carrier gas ； the injector temperature was set at 270 ℃，with flow rate of carrier gas 1 mL/min by temperature programmed ；the sample size was 1 μL，and split ratio was 1 ∶ 10. RESULTS：The linear ranges of apigenin ，piperine，eucalyptol and cumin aldehyde were 12.5-200 μg/g/mL（r＝0.999 6），87.3-139.7 μg/mL（r＝0.999 9），136-2 187 μg/mL（r＝0.999 9），39-635 μg/mL（r＝0.999 9）， respectively. The quantitation limits were 0.02，0.06，0.06，0.12 μg/mL，respectively. The detection limits were 0.01，0.02，0.03， 0.04 μg/mL. RSDs of precision，stability and reproducibility tests were all less than 4％. The recovery rates of the samples were 89.26％ -97.26％（RSD＝2.69％ ，n＝6），94.20％ -104.01％（RSD＝3.64％ ，n＝6），98.51％ -110.11％（RSD＝3.87％ ，n＝6）， 95.76％-107.82％（RSD＝4.12％，n＝6），respectively. The contents of above components were 0.769-0.828，7.741-7.981，5.284 7- 5.846 6，1.038 6-1.101 2 mg/g（n＝3）. CONCLUSIONS：The established method is simple and feasible ，and can be used for quality control of different parts of Mongolian medicine Sugmel- 3 decoction.